Here’s how analysts see Fate Therapeutics, Inc. (NASDAQ:FATE) after this past week.

August 10, 2018 - By Bradley Stiles

Investors sentiment increased to 2.08 in Q1 2018. Its up 0.50, from 1.58 in 2017Q4. It increased, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 23 funds opened positions while 31 raised stakes. 36.46 million shares or 12.96% more from 32.27 million shares in 2017Q4 were reported.
The Minnesota-based Ameriprise Financial has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). 95,154 were accumulated by Parametric Portfolio Associates Ltd Co. 276,690 were accumulated by Natl Bank Of New York Mellon Corporation. Financial Bank Of America Corporation De has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 10,400 shares. Franklin Resource invested in 0.03% or 5.85 million shares. Redmile Group Lc invested 2.51% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Td Asset Mngmt Inc accumulated 41,600 shares or 0% of the stock. Rhumbline Advisers reported 44,386 shares. Virtu Fincl Ltd Liability Com has 16,521 shares for 0.01% of their portfolio. 104,647 were accumulated by Wells Fargo And Com Mn. 683 Mngmt Limited Co accumulated 993,711 shares. Comml Bank Of Montreal Can invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Credit Suisse Ag reported 17,842 shares. Bridgeway Mngmt holds 0.02% or 202,000 shares. 1,500 are owned by Community Bankshares Na.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 7 analysts covering Fate Therapeutics (NASDAQ:FATE), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Fate Therapeutics has $20 highest and $1200 lowest target. $18.17’s average target is 59.11% above currents $11.42 stock price. Fate Therapeutics had 11 analyst reports since March 6, 2018 according to SRatingsIntel. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Hold” rating by H.C. Wainwright on Thursday, March 29. The firm earned “Outperform” rating on Tuesday, March 6 by BMO Capital Markets. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Hold” rating given on Tuesday, March 6 by Raymond James. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Buy” rating given on Tuesday, March 6 by Piper Jaffray. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Wednesday, May 16 with “Buy” rating. As per Tuesday, March 6, the company rating was maintained by Wedbush. Wells Fargo maintained the shares of FATE in report on Friday, April 6 with “Buy” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Buy” rating by Piper Jaffray on Thursday, March 15. The company was downgraded on Tuesday, March 6 by H.C. Wainwright. On Tuesday, March 20 the stock rating was maintained by H.C. Wainwright with “Hold”. Below is a list of Fate Therapeutics, Inc. (NASDAQ:FATE) latest ratings and price target changes.

01/08/2018 Broker: Citigroup Rating: Buy New Target: $20 Initiates Coverage On
16/05/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0000 Maintain
06/04/2018 Broker: Wells Fargo Rating: Buy New Target: $18.0000 Maintain
29/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $12.0000 Maintain
20/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $12.0 Maintain
15/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
06/03/2018 Broker: Raymond James Rating: Hold Downgrade
06/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
06/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $7 New Target: $20 Maintain
06/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral New Target: $12 Downgrade

The stock decreased 0.35% or $0.04 during the last trading session, reaching $11.42. About 282,034 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 233.04% since August 10, 2017 and is uptrending. It has outperformed by 220.47% the S&P500.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $610.05 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

More important recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Benzinga.com which released: “77 Biggest Movers From Yesterday” on August 08, 2018, also Nasdaq.com published article titled: “Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress”, Nasdaq.com published: “Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference” on August 07, 2018. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) was released by: Nasdaq.com and their article: “Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty …” with publication date: July 27, 2018.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: